In 1 study, LSC17 score was higher in adverse-risk patients with t(6;9) AML than in favorable-risk NPM1-mutated AML, with the caveat that only 2 patients were studied from each subtype,55 suggesting a potential association with LSC burden or functional characteristics, as measured by LSC17, resulting from the AML driver. The gene discussed is NPM1; the disease is acute myeloid leukemia.